{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:28:59Z","timestamp":1790814539648,"version":"4.1.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"DOI":"10.1208\/s12249-025-03286-2","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T22:25:19Z","timestamp":1764973519000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Enhanced Efficacy and Safety: Cabazitaxel Nanodispersions as a Novel Therapeutic Platform against Prostate Cancer"],"prefix":"10.1208","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-6879-8479","authenticated-orcid":false,"given":"Youfa","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6127-609X","authenticated-orcid":false,"given":"Yanting","family":"Kuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7724-8066","authenticated-orcid":false,"given":"Hang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1571-3531","authenticated-orcid":false,"given":"Junyi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3102-535X","authenticated-orcid":false,"given":"Bingjie","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5992-6405","authenticated-orcid":false,"given":"Ruobei","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1797-4059","authenticated-orcid":false,"given":"Jiali","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5603-745X","authenticated-orcid":false,"given":"Zongguang","family":"Tai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2875-355X","authenticated-orcid":false,"given":"Xin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"key":"3286_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7\u201330. https:\/\/doi.org\/10.3322\/caac.21590.","journal-title":"CA Cancer J Clin"},{"key":"3286_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27175730","volume":"27","author":"M Sekhoacha","year":"2022","unstructured":"Sekhoacha M, Riet K, Motloung P, Gumenku L, Adegoke A, Mashele S. Prostate cancer review: genetics, diagnosis, treatment options, and alternative approaches. Molecules. 2022;27:5730. https:\/\/doi.org\/10.3390\/molecules27175730.","journal-title":"Molecules"},{"key":"3286_CR3","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.eururo.2019.08.005","volume":"77","author":"MB Culp","year":"2020","unstructured":"Culp MB, Soerjomataram I, Efstathiou JA, Bray F, Jemal A. Recent global patterns in prostate cancer incidence and mortality rates. Eur Urol. 2020;77:38\u201352. https:\/\/doi.org\/10.1016\/j.eururo.2019.08.005.","journal-title":"Eur Urol"},{"key":"3286_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15020461","volume":"15","author":"P Posdzich","year":"2023","unstructured":"Posdzich P, Darr C, Hilser T, Wahl M, Herrmann K, Hadaschik B, et al. Metastatic prostate cancer-a review of current treatment options and promising new approaches. Cancers (Basel). 2023;15:461. https:\/\/doi.org\/10.3390\/cancers15020461.","journal-title":"Cancers (Basel)"},{"key":"3286_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-022-02406-1","volume":"41","author":"S Mirzaei","year":"2022","unstructured":"Mirzaei S, Paskeh MDA, Okina E, Gholami MH, Hushmandi K, Hashemi M, et al. Molecular landscape of lncRNAs in prostate cancer: a focus on pathways and therapeutic targets for intervention. J Exp Clin Cancer Res. 2022;41:214. https:\/\/doi.org\/10.1186\/s13046-022-02406-1.","journal-title":"J Exp Clin Cancer Res"},{"key":"3286_CR6","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.tips.2016.03.003","volume":"37","author":"J Kroon","year":"2016","unstructured":"Kroon J, Kooijman S, Cho N-J, Storm G, Van Der Pluijm G. Improving taxane-based chemotherapy in castration-resistant prostate cancer. Trends Pharmacol Sci. 2016;37:451\u201362. https:\/\/doi.org\/10.1016\/j.tips.2016.03.003.","journal-title":"Trends Pharmacol Sci"},{"key":"3286_CR7","doi-asserted-by":"publisher","first-page":"357","DOI":"10.2147\/CMAR.S49321","volume":"5","author":"S Alken","year":"2013","unstructured":"Alken S, Kelly CM. Benefit risk assessment and update on the use of docetaxel in the management of breast cancer. Cancer Manag Res. 2013;5:357\u201365. https:\/\/doi.org\/10.2147\/CMAR.S49321.","journal-title":"Cancer Manag Res"},{"key":"3286_CR8","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1038\/nrurol.2014.144","volume":"11","author":"S Oudard","year":"2014","unstructured":"Oudard S, Angelergues A. PROSTATE CANCER Cabazitaxel-the taxane of choice in the new mCRPC landscape? Nat Rev Urol. 2014;11:370\u20132. https:\/\/doi.org\/10.1038\/nrurol.2014.144.","journal-title":"Nat Rev Urol"},{"key":"3286_CR9","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1158\/1535-7163.MCT-14-0155","volume":"14","author":"GE Duran","year":"2015","unstructured":"Duran GE, Wang YC, Francisco EB, Rose JC, Martinez FJ, Coller J, et al. Mechanisms of resistance to cabazitaxel. Mol Cancer Ther. 2015;14:193\u2013201. https:\/\/doi.org\/10.1158\/1535-7163.MCT-14-0155.","journal-title":"Mol Cancer Ther"},{"key":"3286_CR10","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1093\/jb\/mvab025","volume":"170","author":"S Endo","year":"2021","unstructured":"Endo S, Kawai M, Hoshi M, Segawa J, Fujita M, Matsukawa T, et al. Targeting Nrf2-antioxidant signalling reverses acquired cabazitaxel resistance in prostate cancer cells. J Biochem. 2021;170:89\u201396. https:\/\/doi.org\/10.1093\/jb\/mvab025.","journal-title":"J Biochem"},{"key":"3286_CR11","doi-asserted-by":"publisher","first-page":"6574","DOI":"10.1158\/1078-0432.CCR-12-1584","volume":"18","author":"AC Mita","year":"2012","unstructured":"Mita AC, Figlin R, Mita MM. Cabazitaxel: more than a new taxane for metastatic castrate-resistant prostate cancer? Clin Cancer Res. 2012;18:6574\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-1584.","journal-title":"Clin Cancer Res"},{"key":"3286_CR12","doi-asserted-by":"publisher","first-page":"2973","DOI":"10.1158\/1078-0432.CCR-12-3146","volume":"19","author":"P Vrignaud","year":"2013","unstructured":"Vrignaud P, S\u00e9miond D, Lejeune P, Bouchard H, Calvet L, Combeau C, et al. Preclinical antitumor activity of cabazitaxel, a semisynthetic taxane active in taxane-resistant tumors. Clin Cancer Res. 2013;19:2973\u201383. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-3146.","journal-title":"Clin Cancer Res"},{"key":"3286_CR13","doi-asserted-by":"publisher","first-page":"117","DOI":"10.2147\/DDDT.S13029","volume":"5","author":"CJ Paller","year":"2011","unstructured":"Paller CJ, Antonarakis ES. Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer. Drug Des Devel Ther. 2011;5:117\u201324. https:\/\/doi.org\/10.2147\/DDDT.S13029.","journal-title":"Drug Des Devel Ther"},{"key":"3286_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics11030141","volume":"11","author":"N Kommineni","year":"2019","unstructured":"Kommineni N, Mahira S, Domb A, Khan W. Cabazitaxel-loaded nanocarriers for cancer therapy with reduced side effects. Pharmaceutics. 2019;11:141. https:\/\/doi.org\/10.3390\/pharmaceutics11030141.","journal-title":"Pharmaceutics"},{"key":"3286_CR15","doi-asserted-by":"publisher","first-page":"38306","DOI":"10.18632\/oncotarget.9439","volume":"7","author":"A Ghoochani","year":"2016","unstructured":"Ghoochani A, Hatipoglu Majernik G, Sehm T, Wach S, Buchfelder M, Taubert H, et al. Cabazitaxel operates anti-metastatic and cytotoxic via apoptosis induction and stalls brain tumor angiogenesis. Oncotarget. 2016;7:38306\u201318. https:\/\/doi.org\/10.18632\/oncotarget.9439.","journal-title":"Oncotarget"},{"key":"3286_CR16","first-page":"1297","volume":"8","author":"R Chen","year":"2018","unstructured":"Chen R, Cheng Q, Owusu-Ansah KG, Chen J, Song G, Xie H, et al. Cabazitaxel, a novel chemotherapeutic alternative for drug-resistant hepatocellular carcinoma. Am J Cancer Res. 2018;8:1297\u2013306.","journal-title":"Am J Cancer Res"},{"key":"3286_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2013.00226","volume":"3","author":"CA Kunos","year":"2013","unstructured":"Kunos CA, Stefan T, Jacobberger JW. Cabazitaxel-induced stabilization of microtubules enhances radiosensitivity in ovarian cancer cells. Front Oncol. 2013;3:226. https:\/\/doi.org\/10.3389\/fonc.2013.00226.","journal-title":"Front Oncol"},{"issue":"44","key":"3286_CR18","doi-asserted-by":"publisher","first-page":"10161","DOI":"10.1039\/C4CE01279H","volume":"16","author":"U Baisch","year":"2014","unstructured":"Baisch U, Vella-Zarb L. Towards understanding P-gp resistance: a case study of the antitumour drug cabazitaxel. CrystEngComm. 2014;16(44):10161\u20134. https:\/\/doi.org\/10.1039\/C4CE01279H.","journal-title":"CrystEngComm"},{"key":"3286_CR19","doi-asserted-by":"publisher","first-page":"230","DOI":"10.4103\/0976-500X.119704","volume":"4","author":"A Abidi","year":"2013","unstructured":"Abidi A. Cabazitaxel: a novel taxane for metastatic castration-resistant prostate cancer-current implications and future prospects. J Pharmacol Pharmacother. 2013;4:230\u20137. https:\/\/doi.org\/10.4103\/0976-500X.119704.","journal-title":"J Pharmacol Pharmacother"},{"key":"3286_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114392","volume":"160","author":"M Hashemi","year":"2023","unstructured":"Hashemi M, Zandieh MA, Talebi Y, Rahmanian P, Shafiee SS, Nejad MM, et al. Paclitaxel and docetaxel resistance in prostate cancer: molecular mechanisms and possible therapeutic strategies. Biomed Pharmacother. 2023;160:114392. https:\/\/doi.org\/10.1016\/j.biopha.2023.114392.","journal-title":"Biomed Pharmacother"},{"key":"3286_CR21","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.ijpharm.2015.12.073","volume":"499","author":"B Zhuang","year":"2016","unstructured":"Zhuang B, Du L, Xu H, Xu X, Wang C, Fan Y, et al. Self-assembled micelle loading Cabazitaxel for therapy of lung cancer. Int J Pharm. 2016;499:146\u201355. https:\/\/doi.org\/10.1016\/j.ijpharm.2015.12.073.","journal-title":"Int J Pharm"},{"key":"3286_CR22","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/S1081-1206(10)61024-1","volume":"95","author":"EA Coors","year":"2005","unstructured":"Coors EA, Seybold H, Merk HF, Mahler V. Polysorbate 80 in medical products and nonimmunologic anaphylactoid reactions. Ann Allergy Asthma Immunol. 2005;95:593\u20139. https:\/\/doi.org\/10.1016\/S1081-1206(10)61024-1.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"3286_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/wnan.1854","volume":"15","author":"B Sun","year":"2023","unstructured":"Sun B, Lovell JF, Zhang Y. Current development of cabazitaxel drug delivery systems. WIREs Nanomed Nanobiotechnol. 2023;15:e1854. https:\/\/doi.org\/10.1002\/wnan.1854.","journal-title":"WIREs Nanomed Nanobiotechnol"},{"key":"3286_CR24","doi-asserted-by":"publisher","DOI":"10.1088\/1748-605X\/abe396","author":"Y Chen","year":"2021","unstructured":"Chen Y, Pan Y, Hu D, Peng J, Hao Y, Pan M, et al. Recent progress in nanoformulations of cabazitaxel. Biomed Mater. 2021. https:\/\/doi.org\/10.1088\/1748-605X\/abe396.","journal-title":"Biomed Mater"},{"key":"3286_CR25","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.9690.1","volume":"6","author":"Y-F Wang","year":"2017","unstructured":"Wang Y-F, Liu L, Xue X, Liang X-J. Nanoparticle-based drug delivery systems: what can they really do in vivo? F1000Res. 2017;6:681. https:\/\/doi.org\/10.12688\/f1000research.9690.1.","journal-title":"F1000Res"},{"key":"3286_CR26","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2174\/1574892817666220713150521","volume":"18","author":"J Liu","year":"2022","unstructured":"Liu J, Li S, Wang J, Li N, Zhou J, Chen H. Application of nano drug delivery system (NDDS) in cancer therapy: a perspective. Recent Pat Anticancer Drug Discov. 2022;18:125\u201332. https:\/\/doi.org\/10.2174\/1574892817666220713150521.","journal-title":"Recent Pat Anticancer Drug Discov"},{"key":"3286_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107100","volume":"201","author":"L Huang","year":"2024","unstructured":"Huang L, Huang X-H, Yang X, Hu J-Q, Zhu Y-Z, Yan P-Y, et al. Novel nano-drug delivery system for natural products and their application. Pharmacol Res. 2024;201:107100. https:\/\/doi.org\/10.1016\/j.phrs.2024.107100.","journal-title":"Pharmacol Res"},{"key":"3286_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2023.1177151","volume":"11","author":"X Cheng","year":"2023","unstructured":"Cheng X, Xie Q, Sun Y. Advances in nanomaterial-based targeted drug delivery systems. Front Bioeng Biotechnol. 2023;11:1177151. https:\/\/doi.org\/10.3389\/fbioe.2023.1177151.","journal-title":"Front Bioeng Biotechnol"},{"key":"3286_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2020.119814","volume":"589","author":"Z Yang","year":"2020","unstructured":"Yang Z, Chi D, Wang Q, Guo X, Lv Q, Wang Y. Improved antitumor activity and tolerability of cabazitaxel derived remote-loading liposomes. Int J Pharm. 2020;589:119814. https:\/\/doi.org\/10.1016\/j.ijpharm.2020.119814.","journal-title":"Int J Pharm"},{"key":"3286_CR30","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.ajps.2018.10.004","volume":"14","author":"X Yin","year":"2019","unstructured":"Yin X, Luo L, Li W, Yang J, Zhu C, Jiang M, et al. A cabazitaxel liposome for increased solubility, enhanced antitumor effect and reduced systemic toxicity. Asian J Pharm Sci. 2019;14:658\u201367. https:\/\/doi.org\/10.1016\/j.ajps.2018.10.004.","journal-title":"Asian J Pharm Sci"},{"key":"3286_CR31","doi-asserted-by":"publisher","first-page":"490","DOI":"10.3892\/mmr.2018.9689","volume":"19","author":"Y Cheng","year":"2019","unstructured":"Cheng Y, Ou Z, Li Q, Yang J, Hu M, Zhou Y, Zhuang X, Zhang ZJ, Guan S. Cabazitaxel liposomes with aptamer modification enhance tumor-targeting efficacy in nude mice. Mol Med Rep. 2019;19:490\u20138. https:\/\/doi.org\/10.3892\/mmr.2018.9689.","journal-title":"Mol Med Rep"},{"key":"3286_CR32","doi-asserted-by":"publisher","first-page":"3451","DOI":"10.2147\/IJN.S105420","volume":"11","author":"N Qu","year":"2016","unstructured":"Qu N, Lee RJ, Sun Y, Cai G, Wang J, Wang M, Lu J, Meng Q, Teng L, Wang D, Teng L. Cabazitaxel-loaded human serum albumin nanoparticles as a therapeutic agent against prostate cancer. Int J Nanomedicine. 2016;11:3451\u20139. https:\/\/doi.org\/10.2147\/IJN.S105420.","journal-title":"Int J Nanomedicine"},{"key":"3286_CR33","doi-asserted-by":"publisher","first-page":"294","DOI":"10.2174\/1871520616666160526103102","volume":"17","author":"N Qu","year":"2017","unstructured":"Qu N, Sun Y, Xie J, Teng L. Preparation and evaluation of in vitro self-assembling HSA nanoparticles for Cabazitaxel. Anticancer Agents Med Chem. 2017;17:294\u2013300. https:\/\/doi.org\/10.2174\/1871520616666160526103102.","journal-title":"Anticancer Agents Med Chem"},{"key":"3286_CR34","unstructured":"Zhou G, Jin X, Zhu P, et al. Human Serum Albumin Nanoparticles as a Novel Delivery System for Cabazitaxel. Anticancer Res. 2016;36(4):1649-1656. https:\/\/ar.iiarjournals.org\/content\/36\/4\/1649.long."},{"key":"3286_CR35","unstructured":"Khopade AJ, Arulsudar N, Bhowmick S. Nanodispersion of drug and process for its preparation, US8778364B2, July 15, 2014. https:\/\/patents.google.com\/patent\/US8778364B2\/en."},{"key":"3286_CR36","unstructured":"Ke X, Wang J, Yan F. Filtration by microspore film for determination of the entrapment efficiency of docetaxel liposomes. Chinese Chin J Mod Appl Pharm. 2008;314\u20136."},{"key":"3286_CR37","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.jcma.2014.03.008","volume":"77","author":"S-K Zhou","year":"2014","unstructured":"Zhou S-K, Chen W-H, Shi Z-D, Wang S-P, Li L, Wen X-F, et al. Silencing the expression of Cbl-b enhances the immune activation of T lymphocytes against RM-1 prostate cancer cells in vitro. J Chin Med Assoc. 2014;77:630\u20136. https:\/\/doi.org\/10.1016\/j.jcma.2014.03.008.","journal-title":"J Chin Med Assoc"},{"key":"3286_CR38","doi-asserted-by":"publisher","first-page":"12048","DOI":"10.3390\/molecules190812048","volume":"19","author":"H Chen","year":"2014","unstructured":"Chen H, Liang X, Xu F, Xu B, He X, Huang B, et al. Synthesis and cytotoxic activity evaluation of novel arylpiperazine derivatives on human prostate cancer cell lines. Molecules. 2014;19:12048\u201364. https:\/\/doi.org\/10.3390\/molecules190812048.","journal-title":"Molecules"},{"key":"3286_CR39","doi-asserted-by":"publisher","first-page":"7656","DOI":"10.7150\/thno.44567","volume":"10","author":"Y Li","year":"2020","unstructured":"Li Y, Zhang B, Xiang L, Xia S, Kucuk O, Deng X, et al. TGF-\u03b2 causes docetaxel resistance in prostate cancer via the induction of Bcl-2 by acetylated KLF5 and protein stabilization. Theranostics. 2020;10:7656\u201370. https:\/\/doi.org\/10.7150\/thno.44567.","journal-title":"Theranostics"},{"key":"3286_CR40","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1007\/s13346-018-0562-0","volume":"8","author":"Y Liu","year":"2018","unstructured":"Liu Y, Xie B, Li L, Zhang X, Zhang Y, He H, et al. PEGylated lipid microspheres loaded with cabazitaxel for intravenous administration: stability, bioavailability, antitumor efficacy, and toxicity. Drug Deliv Transl Res. 2018;8:1365\u201379. https:\/\/doi.org\/10.1007\/s13346-018-0562-0.","journal-title":"Drug Deliv Transl Res"},{"key":"3286_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2023.113732","volume":"234","author":"S Shah","year":"2024","unstructured":"Shah S, Famta P, Kumar R, Sharma A, Vambhurkar G, Pandey G, et al. Quality by design fostered fabrication of cabazitaxel loaded pH-responsive improved nanotherapeutics against prostate cancer. Colloids Surf B Biointerfaces. 2024;234:113732. https:\/\/doi.org\/10.1016\/j.colsurfb.2023.113732.","journal-title":"Colloids Surf B Biointerfaces"},{"key":"3286_CR42","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/0272-0590(90)90263-j","volume":"14","author":"DM Hoover","year":"1990","unstructured":"Hoover DM, Gardner JB, Timmerman TL, Klepfer JA, Laska DA, White SL, McGrath JP, Buening MK, Williams PD. Comparison of in vitro and in vivo models to assess venous irritation of parenteral antibiotics. Fundam Appl Toxicol. 1990;14:589\u201397. https:\/\/doi.org\/10.1016\/0272-0590(90)90263-j.","journal-title":"Fundam Appl Toxicol"},{"key":"3286_CR43","doi-asserted-by":"publisher","first-page":"3689","DOI":"10.2147\/IJN.S33228","volume":"7","author":"X Song","year":"2012","unstructured":"Song X, Jiang Y, Ren C, Sun X, Zhang Q, Gong T, Zhang Z. Nimodipine-loaded mixed micelles: formulation, compatibility, pharmacokinetics, and vascular irritability study. Int J Nanomedicine. 2012;7:3689\u201399. https:\/\/doi.org\/10.2147\/IJN.S33228.","journal-title":"Int J Nanomedicine"},{"key":"3286_CR44","unstructured":"A lipid microsphere vehicle for vinorelbine: Stability, safety and pharmacokinetics - PubMed, (n.d.). https:\/\/pubmed.ncbi.nlm.nih.gov\/17719191\/ (Accessed July 3, 2025)."},{"key":"3286_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3677-7","volume":"17","author":"WJ Aston","year":"2017","unstructured":"Aston WJ, Hope DE, Nowak AK, Robinson BW, Lake RA, Lesterhuis WJ. A systematic investigation of the maximum tolerated dose of cytotoxic chemotherapy with and without supportive care in mice. BMC Cancer. 2017;17:684. https:\/\/doi.org\/10.1186\/s12885-017-3677-7.","journal-title":"BMC Cancer"},{"key":"3286_CR46","doi-asserted-by":"publisher","first-page":"3489","DOI":"10.1200\/JCO.22.00371","volume":"40","author":"J Fourie Zirkelbach","year":"2022","unstructured":"Fourie Zirkelbach J, Shah M, Vallejo J, Cheng J, Ayyoub A, Liu J, et al. Improving dose-optimization processes used in oncology drug development to minimize toxicity and maximize benefit to patients. J Clin Oncol. 2022;40:3489\u2013500. https:\/\/doi.org\/10.1200\/JCO.22.00371.","journal-title":"J Clin Oncol"},{"key":"3286_CR47","unstructured":"BC-N102 suppress breast cancer tumorigenesis by interfering with cell cycle regulatory proteins and hormonal signaling, and induction of time-course arrest of cell cycle at G1\/G0 phase - PubMed, (n.d.). https:\/\/pubmed.ncbi.nlm.nih.gov\/34421361\/ (Accessed July 3, 2025)."},{"key":"3286_CR48","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.2147\/IJN.S298093","volume":"16","author":"M Xu","year":"2021","unstructured":"Xu M, Yao C, Zhang W, Gao S, Zou H, Gao J. Anti-cancer activity based on the high Docetaxel loaded poly(2-oxazoline)s micelles. Int J Nanomedicine. 2021;16:2735\u201349. https:\/\/doi.org\/10.2147\/IJN.S298093.","journal-title":"Int J Nanomedicine"},{"key":"3286_CR49","doi-asserted-by":"publisher","unstructured":"Wan Z, Xie F, Wang L, Zhang G, Zhang H. Preparation and Evaluation of Cabazitaxel-Loaded Bovine Serum Albumin Nanoparticles for Prostate Cancer. Int J Nanomed. 2020;15. https:\/\/doi.org\/10.2147\/IJN.S258856.","DOI":"10.2147\/IJN.S258856"},{"key":"3286_CR50","unstructured":"Cabazitaxel-conjugated nanoparticles for docetaxel-resistant and bone metastatic prostate cancer - PubMed, (n.d.).  https:\/\/pubmed.ncbi.nlm.nih.gov\/28965854\/.  Accessed 3 July 2025."},{"key":"3286_CR51","doi-asserted-by":"publisher","first-page":"5091","DOI":"10.21873\/anticanres.14512","volume":"40","author":"T Miyao","year":"2020","unstructured":"Miyao T, Koike H, Sekine Y, Ohtsu A, Oka D, Suzuki K. YM155 reverses cabazitaxel resistance in castration-resistant prostate cancer by reducing survivin expression. Anticancer Res. 2020;40:5091\u20135. https:\/\/doi.org\/10.21873\/anticanres.14512.","journal-title":"Anticancer Res"},{"key":"3286_CR52","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.cis.2008.10.005","volume":"147","author":"T Tadros","year":"2009","unstructured":"Tadros T. Polymeric surfactants in disperse systems. Adv Colloid Interface Sci. 2009;147:281\u201399. https:\/\/doi.org\/10.1016\/j.cis.2008.10.005.","journal-title":"Adv Colloid Interface Sci"},{"key":"3286_CR53","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1049\/mnl.2011.0551","volume":"7","author":"S Xiaofang","year":"2012","unstructured":"Xiaofang S. Encapsulation of CdTe quantum dots in polyvinylpyrrolidone nanoparticle for live cell imaging. Micro Nano Lett. 2012;7:137\u201341. https:\/\/doi.org\/10.1049\/mnl.2011.0551.","journal-title":"Micro Nano Lett"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-025-03286-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-025-03286-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-025-03286-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T18:04:04Z","timestamp":1770314644000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12249-025-03286-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["3286"],"URL":"https:\/\/doi.org\/10.1208\/s12249-025-03286-2","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,5]]},"assertion":[{"value":"3 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"50"}}